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Abstract: Long-term exposition to morphine elicits structural and synaptic plasticity in reward-related
regions of the brain, playing a critical role in addiction. However, morphine-induced neuroadaptations in the dorsal striatum have been poorly studied despite its key function in drug-related habit
learning. Here, we show that prolonged treatment with morphine triggered the retraction of the
dendritic arbor and the loss of dendritic spines in the dorsal striatal projection neurons (MSNs).
In an attempt to extend previous findings, we also explored whether the dopamine D4 receptor
(D4 R) could modulate striatal morphine-induced plasticity. The combined treatment of morphine
with the D4 R agonist PD168,077 produced an expansion of the MSNs dendritic arbors and restored
dendritic spine density. At the electrophysiological level, PD168,077 in combination with morphine
altered the electrical properties of the MSNs and decreased their excitability. Finally, results from the
sustantia nigra showed that PD168,077 counteracted morphine-induced upregulation of µ opioid
receptors (MOR) in striatonigral projections and downregulation of G protein-gated inward rectifier
K+ channels (GIRK1 and GIRK2) in dopaminergic cells. The present results highlight the key function
of D4 R modulating morphine-induced plasticity in the dorsal striatum. Thus, D4 R could represent a
valuable pharmacological target for the safety use of morphine in pain management.
Keywords: dopamine; morphine; addiction; dopamine D4 receptor; caudate putamen; plasticity;
receptor–receptor interaction
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1. Introduction
Long-lasting use of drugs of abuse elicits persistent molecular and cellular neuroadaptive changes within discrete brain regions—e.g., ventral tegmental area (VTA), ventral
and dorsal striatum, prefrontal cortex, amygdala, or hippocampus—which have been
identified as the neural substrate for behavioral abnormalities driving addiction, drug
craving, and relapse [1]. Such drug-mediated alterations affect several neurotransmitters
systems—e.g., dopaminergic, GABAergic or glutamatergic systems—signal transduction
pathways, neuronal activity, cellular architecture remodeling and synaptic strength [2–6].
Although there is an extensive amount of data regarding drug-mediated modifications, yet
it is a major challenge to understand how this wide variety of neuroadaptations converge
and operate together in the different stages of the addiction cycle—binge/intoxication’,
‘withdrawal/negative affect’, and ‘preoccupation/anticipation’ [1].
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Most of the studies in drug-induced neuroadaptations have preferentially focused
in the traditional areas of the reward system—i.e., mesolimbic dopaminergic pathway
arising from the VTA which provides projections into the nucleus accumbens (NAc), the
major component of the ventral striatum. However, nowadays major attention is also
being given to the caudate putamen (CPu)—dorsal striatum—since this region play a
pivotal role in goal-directed behavior, drug-related habit learning and automaticity of
drug consumption [7–9]. Therefore, it has been hypothesized that the transition from
recreational drug use to compulsive drug abuse, and thus the consolidation of drug-related
instrumental behaviors, comprises a transition from the ventral to the dorsal areas of the
striatum activity [10].
Morphine is one of the most powerful analgesic drugs used to relieve pain though
highly addictive, making difficult to design a proper prescription schedule. Indeed, longterm morphine consumption promotes neurobiological adaptations including synaptic and
structural plasticity in some brain regions, which ultimately contribute to the development
of addiction [5,11]. So far, it has been reported that morphine produces neuronal morphological changes, such as alterations of the dendritic arbor complexity and dendritic spines at
nucleus accumbens (NAc) medium spiny neurons (MSNs) and at cortical and hippocampal
pyramidal cells [2,5,12–15]. Chronic morphine treatment also produces neuro-adaptative
changes in dopamine neurons of the ventral tegmental area (VTA) and substantia nigra
pars compacta (SNc), which correlates with altered neuron excitability and dopamine efflux [16–18]. Though not as extensively investigated as the NAc, the CPu also undergoes
a morphine-induced dysregulation of nigral dopamine inputs and signaling [16,19–21].
However, there is no evidence on whether this drug potentially produces morphological plasticity on dorsal striatal MSNs similar to those described in other brain regions as
described above.
The identification of novel strategies to suppress the addictive properties of morphine
has emerged as a hot topic in the current investigation in opioid addiction [22]. Several
studies have highlighted the dopamine D4 receptor (D4 R) as a key modulator in the
addicted behavior, since the deficiency in this receptor seems to increase the susceptibility
to the development of drugs abuse [23,24]. Of high interest is the evidence that the
selective stimulation of the D4 R decreases morphine-induced hyperlocomotion, reward and
withdrawal syndrome, without interfering with the analgesic properties of morphine [16].
These results were strengthened by the demonstration that D4 R stimulation counteracts
morphine-induced activation of the nigrostriatal pathway leading to a restoring of dorsal
striatal dopamine tone, and also by the ability of the D4 R to modulate molecular alterations
and long-term µ opioid receptor (MOR) sensitization in the CPu [16,25–27]. Despite these
evidences, the exact molecular mechanisms by which D4 R appears to prevent the addictive
effects of morphine are not yet fully understood, but an antagonistic D4 R-MOR interaction
in the CPu might occur through the formation of heteroreceptor complexes [16,28,29].
In this perspective, the aim of the present study was to determine how the continuous
exposure to morphine would induce structural plasticity and changes in the intrinsic
membrane excitability and firing properties of the dorsal striatal MSNs, and whether these
neuroadaptations were modulated by D4 R activation.
2. Materials and Methods
2.1. Animals
Experiments were conducted in 1–2 month-old male Sprague-Dawley rats (Charles River,
Barcelona, Spain). The animals were maintained on a standard light/dark cycle (12/12 h),
constant room temperature (20 ± 2 ◦ C) and relative humidity (65 ± 75%) with food and
water available ad libitum. Animal care and procedures were conducted in accordance
with protocols approved by the Ethical Committee of the University of Málaga (CEUMA
79-2019-A) and the University of Bordeaux (CEEA-50), guidelines from the European Union
Council Directive 86/609/EEC, as well as the Spanish Government (R.D. 53/2013).
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2.2. Drug Administration
Morphine sulfate was obtained from Alcaliber S.A. (Madrid, Spain) subsequent to
receiving authorization from Spanish Agency of Medicines and Medical Devices (Spanish
Government). PD168,077 maleate was supplied by Tocris Bioscience (Avonmouth, UK).
The specificity of PD168,077 as a D4 R agonist has been extensively proved in prior works
using the highly selective antagonist L745,870 [16,25–27]. All drugs were dissolved in the
vehicle solution consistent in 2% dimethyl sulfoxide (DMSO) and 0.9% NaCl. We have
demonstrated in a previous report that this amount of DMSO had no effect on receptors
function [30].
Rats received 7 or 14 days of continuous administration of vehicle, morphine (20 mg/kg/d)
and/or PD168,077 (1 mg/kg/d) by an osmotic pump (Alzet® osmotic pumps, Cupertino,
CA, USA) that was subcutaneously implanted under deep anesthesia (75 mg/kg ketamine
and 0.5 mg/kg medetomidine, i.p.) between the shoulder blades. Skin was sutured with
sterile non absorbable suture and the surgical site was disinfected with a topical antiseptic
(povidone iodine 10% solution). During the surgery and recovery, animals were kept warn
using a heating pad. Animals were sacrificed the last day of the continuous administration
of drugs.
2.3. Electrophysiology
2.3.1. Slice Preparation
Rats (n = 19) were sacrificed by decapitation under deep anesthesia (4% isoflurane)
after 14 days of continuous drugs treatments. Brains were removed and transferred into
an ice-cold artificial cerebrospinal fluid (ASCF), equilibrated with 95% O2 and 5% CO2 ,
and containing in mM: 250 sucrose, 26 NaHCO3 , 7 MgCl2 , 2 KCl, 1.15 NaH2 PO4 , 0.5 CaCl2 ,
1 glucose at pH 7.4. Coronal brain sections (350 µm thick) at the rostral CPu level (+1.7 to
+1.20 mm from Bregma) were obtained with a microtome (VT1200S; Leica Microsystems,
Germany) and left in ACSF containing (in mM): 124 NaCl, 26 NaHCO3 , 1.3 MgCl2 , 3.6 KCl,
2.4 CaCl2 , 1.25 HEPES, 10 glucose, pH 7.4 gassed with 95% O2 , 5% CO2 until further recording.
2.3.2. Whole-Cell Current-Clamp Recordings
Each section was transferred into a recording chamber and was continuously perfused
with an oxygenated ACSF at a rate of 3.5 mL/min. MSNs within the dorsolateral part of
the CPu were identified by their morphological characteristics under infrared differential
interfere contrast (IR-DIC) optics (Zeiss examiner Z.1).
The patch pipette was filled with a KGluconate-based solution containing (in mM):
140 KGluconate, 3.8 NaCl, 1 MgCl2 , 10 HEPES, 0.1 Na4 EGTA, 2 Mg, 1.5 ATP, and 0.4 Na3 GTP.
The day of the experiment the solution was supplemented by biocytin (2.5–5 mg/mL) and
by Alexa fluor 488 (2 µM) to allow morphological analysis of the recorded cells. The
pH and osmolarity of the pipette solution were 7.3 and 290 mOsm, respectively. The
junction potential between the electrode solution and the external media (empirically
estimated as 13 mV) was not corrected. Electrode signals were low-pass filtered at 4 kHz
and sampled at 20 kHz. Only one neuron was recorded per slice to avoid uncertainty in the
reconstruction phase.
The recordings usually begun in the voltage clamp mode. The neurons were maintained at −80 mV, and 5 successive voltage steps of −10 mV were applied. The average
current response was analyzed off-line and cell capacity (Cm), membrane resistance (Rm)
and access resistance (Ra) were calculated. In some neurons, only current clamp was
used, and these three parameters were calculated from the voltage response to a −25pA
stimulation. In the current clamp mode, incremental currents from −300 to +500 pA
were injected in 25 or 50 pA steps to explore the subthreshold and firing properties of
the neurons. Off line analysis was performed using pClamp V9.2 (Molecular Devices,
San Jose, CA, USA), Origin V7 (OriginLab, Northampton, MA, USA), Prism5 (GraphPad
Software, SanD iego, CA, USA) and R (R Foundation for Statistical Computing, Austria).
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After recording, the slices were rinsed, fixed in paraformaldehyde (2%), and kept frozen at
−20 ◦ C until biocytin revelation.
2.4. Cell Reconstruction and Morphometric Analysis
After the recordings, sections were fixed with 4% paraformaldehyde, rinsed with
0.1 M phosphate-buffered saline, pH 7.4 (PBS) and incubated with streptavidin-conjugated
Alexa Fluor® 488 (Table S1) diluted 1:500 in PBS with 0.1% Triton X-100 and 0.02% sodium
azide for 24 h in the dark. After washing with PBS, the sections were mounted on glass
slides and coverslipped with an aqueous-based mounting medium.
Only completely Alexa Fluor® 488 filled neurons were analyzed. Serial optical sections
(0.1 µm step size) of each neuron were acquired with a laser-scanning confocal microscope (Leica, TCS NT) using a 63 × 1.3 numerical aperture oil-immersion. Images were
acquired at high-resolution, with an image size of 1024 × 1024 pixels, and a voxel size of
0.27 × 0.27 × 1 µm for the x, y, and z axes, respectively. Image stacks were deconvolved
to reduce signal blurring and each cell were three-dimensional reconstructed, traced, and
analyzed using the image analysis system NeuronStudio (Icahn School of Medicine at
Mount Sinai) [31]. For Sholl analysis, the number of intersections were counted between
dendritic branches and a series of concentric spheres, starting at 10 µm from the soma and
at radial increment of 1 µm. To quantify spine density, a digital zoom (6.7-fold augmentation) was applied and at least 10–15 dendritic segments (10 µm length) per branch order
from each neuron were obtained. Each segment was manually inspected and appropriate
corrections made using the NeuronStudio interface. Dendritic protrusions (thin, stubby,
and mushroom spines) were classified according to their shapes: mushroom with large
head and short neck; thin with thin head and long neck; and stubby with large head and
no apparent neck.
2.5. Immunohistochemistry
Animals (n = 24) were transcardially perfused with 0.1 M PBS followed by 4%
paraformaldehyde under deep sodium pentobarbital anesthesia (60 mg/kg, i.p.). The
brains were rapidly removed, overnight post-fixed in the same fixative, cryoprotected in
30% sucrose in PBS (72 h) and frozen in dry ice. Rostro-caudal series of coronal sections
(30 µm thick) were obtained with a freezing microtome (CM 1325, Leica, Weztlar, Germany)
and stored in PBS containing 0.02% sodium azide. Free-floating sections were taken from
the CPu (+1.0 to −0.30 mm from Bregma) and substantia nigra (−5.30 to −5.80 mm from
Bregma) and processed for either single or double immunolabeling procedures.
Details regarding the antibodies used in the present study are listed in Table 1 (primary
antibodies) and Table S1 (secondary antibodies). All primary antibodies were diluted in
phosphate-buffered saline containing 0.2% Triton X-100 (PBS-TX) and 0.1% sodium azide.
2.5.1. Single Immunohistochemical Labeling
Free-floating brain sections were pre-treated for 15 min with 3% H2 O2 , rinsed in 0.1 M
PBS and then incubated in the primary antibody (Table 1) for 24–48 h at room temperature.
After being rinsed in PBS, the sections were incubated for 1 h in the appropriate secondary
biotinylated antibody (Vector Laboratories, Burlingame, CA, USA) (Table S1) diluted
1:500 in PBS-TX. The sections were washed again with PBS and incubated for 1 h in
peroxidase-conjugated streptavidin (Sigma-Aldrich, St. Louis, MO, USA) diluted 1:2000 in
PBS-TX. Peroxidase activity was developed with 0.05% 3,3´-diaminobenzidine (DAB,
Sigma-Aldrich, St. Louis, MO, USA) in the presence of 0.02% H2 O2 and 0.08% nickel
ammonium sulfate. Sections were mounted on gelatin-coated slides, air dried, dehydrated,
and coverslipped with DPX mounting medium.
2.5.2. Double Immunohistochemical Labeling
Selected sections were sequentially incubated with the two primary antibodies of
interest for 24–48 h at room temperature each. After being rinsed in PBS, the sections were
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incubated for 1 h at room temperature in a mixture of the appropriate secondary antibodies
conjugated with Alexa 488 or Alexa 568 (Thermo Fisher, Waltham, MD, USA) (Table S1)
yielding a green or red fluorescent signal, respectively. At the end of the staining, the sections were mounted on glass slides, coversliped with an aqueous-based mounting medium
and observed with a Leica SP8 laser confocal microscopy (Leica, Wetzlar, Germany).
Table 1. Primary antibodies used for immunohistochemistry and western blot.
Antibody

Type

Specie

Source / Reference

Dilution

Calretinin (CR)
Choline acetyltransferase (ChAT)
GIRK1 (Kir3.1)
GIRK2 (Kir3.2)
µ opioid receptor (MOR)
Parvalbumin (PV)
Somatostatin (SS)
Spinophilin
Synaptophysin
Tyrosine hydroxylase (TH)

PolyPolyPolyPolyPolyMonoPolyPolyMonoMono-

G
G
R
R
R
M
G
R
M
M

Swant (CG1)
Millipore (AB144P)
Alomone Labs (AB2040113)
Alomone Labs (AB2040115)
Millipore (PC165L)
Sigma-Aldrich (P3171)
Santa Cruz (sc-7819)
Millipore (06-852)
Abcam (ab8049)
InmunoStar (P22941)

1:10,000 (IF)
1:750 (IF)
1:500 (IMQ, IF)
1:1000 (IMQ, IF)
1:50,000 (IMQ)
1:5000 (IF)
1:5000 (IF)
1:200 (IMQ)
1:2000 (WB)
1:1000 (IF)

Abbreviations: Mono-, monoclonal; Poly-, polyclonal; G, goat; M, mouse; R, rabbit; IMQ: immunohistochemistry;
IF: immunofluorescence; WB: western blot.

2.5.3. Microscopic Analysis and Semi-Quantification
Semi-quantitative analyses of optical density (OD) of immunoreactivity (IR) were
performed, as described elsewhere [30], using the software ImageJ 1.48v (National Institutes
of Health, NIH). The measures were performed form gray-scale photomicrographs obtained
with a digital camera (DS-Fi1, Nikon, Tokyo, Japan) coupled to an optical microscope
(Eclipse E400, Nikon, Tokyo, Japan) (40× objective). All OD values where corrected with
the OD from an immunonegative area and data were expressed as mean percentage OD
of control.
2.6. Western Blot
Animals (n = 16) were sacrificed by decapitation and the brains immediately removed.
The substantia nigra was dissected and homogenized in a lysis buffer containing 2 mM
orthovanadate and a mixture of protease inhibitors (Roche Diagnostics GmbH, Switzerland). After incubating on ice for 30 min, samples were centrifuged at 8000× g for 10 min
at 4 ◦ C. The supernatant was used for western blotting. Equal amounts of protein (50 µg)
was loaded and resolved in 12 % SDS-polyacrylamide gel electrophoresis and then transferred onto PVDF membranes (Hybond-P, GE Healthcare, UK). Membranes were incubated
overnight at 4 ◦ C with a specific primary antibody (Table 1), followed by HRP-conjugated
secondary antibody. Bands of the membranes were visualized using chemiluminescence
detection (ECL, GE Healthcare, UK). Comparisons between the experimental groups were
performed by determining bands immunoreactivity by densitometry with the image analyzing system ImageJ1.48v (NIH).
2.7. Statistical Analysis
Data are expressed as mean ± SEM. Statistical differences (P < 0.05) were assessed by
one-way analysis of variance (ANOVA) followed by Bonferroni t test or Kruskal–Wallis
analysis followed by Dunn’s test for nonparametric data. Statistical analysis and graphs
were generated using Prism 5 (GraphPad Software).
3. Results
3.1. D4 R Activation Results in MSNs Dendritic Arbors Stretching and Prevention of
Morphine-Induced MSNs Dendritic Contraction
Morphine-induced structural plasticity has been previously demonstrated in several
brain regions—e.g., NAc, prefrontal cortex or hippocampus [5,15]. To address whether
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morphine could also produce structural plasticity on striatal projection neurons of the
CPu, we first analyzed MSNs dendritic arborization after 14 days of continuous drug
treatment (Figure 1A). We found that morphine apparently did not alter the total number
of dendrites (Figure 1B), neither the total dendrite length (Figure 1C) nor the number of
nodes (Figure 1D). However, there was a pronounced and significant reduction in the
dendritic volume (by 60%) (Figure 1E). To further explore the impact of morphine on the
dendritic arbor complexity, a morphological analysis was performed considering both the
dendritic branch order and the distance from the soma. Morphine treatment produced both
a remarkable shrinkage of proximal dendrites as a consequence of its shortening (>60% of
reduction in the 1st, 2nd, and 3rd branch order) and volume diminishment (by 50% in the
dendrites directly emanating from the soma) (Figure 1C’–E’).
Given the ability of D4 R activation to prevent morphine-induced impairment of nigral
dopaminergic signaling [16] and some of the molecular maladaptive changes related to
drug addiction [25–27,32], we next studied whether the D4 R agonist PD168,077 could affect
morphine-induced MSNs dendritic arbors remodeling. The continuous administration
(14 days) of PD168,077 alone or in combination with morphine yield a prominent expansion
of the MSNs dendritic arbors (Figure 1A), which was demonstrated by an overall increase in
the number of dendrites (PD168,077: by 23%; morphine + PD168,077: by 33%) (Figure 1B),
total dendritic length (PD168,077: by 47%; morphine + PD168,077: by 46%) (Figure 1C),
and number of nodes (PD168,077: by 41%; morphine + PD168,077: by 37%) (Figure 1D).
Interestingly, these effects were significantly different across the dendritic arbor. Thus,
PD168,077 and morphine + PD168,077 did not modify the morphological characteristics
of proximal dendrites (1st and 2nd branch order) but increased the complexity of distal
dendrites (4th and 5th branch order) (Figure 1B’–D’). As it is shown in Figure 1E–E’, dendritic volume was not altered neither by PD168,077 nor morphine + PD168,077 treatments
compared to controls animals.
3.2. D4 R Activation Counteracts Dendritic Spine Depletion Induced by Morphine
We next analyzed the effects of the continuous treatment (14 days) with morphine
and/or PD168,077 on MSNs spine density (Figure 2A). Spine density was significantly
reduced in the striatal MSNs of morphine-treated animals as compared to control rats
(by 25%) (Figure 2B). This spine loss was observed in distal dendrites (3rd, 4th, 5th, and
6th branch order) (Figure 2C) and it was associated with the selective reduction in stubby
(by 48%) and mushroom (by 42%) spines (Figure 2D). The D4 R agonist produced an even
greater decrease in the overall spine density (by 45%) (Figure 2B), but in this case it occurred throughout the entire dendritic arbor (Figure 2C). The analysis of spine morphology
indicated that such PD168,077-induced lower spine density was due to a decrease in the
number of thin (by 40%), stubby (by 58%) and mushroom (by 60%) spines (Figure 2D).
When PD168,077 was administered together with morphine, spine density was apparently reestablished (Figure 2A–C), as it was observed for thin-shaped spines (Figure 2D).
However, it should be noted that morphine + PD168,077 was unable to restore the loss of
stubby spines and only partially did for mushroom spines (Figure 2D).
Since spinophilin is a protein highly enriched in dendritic spines where it plays a
key role in modulating spine density and synaptic activity [33], we evaluated its possible
regulation by morphine and/or PD168,077. It was showed that the continuous treatment
with morphine or PD168,077 alone downregulated striatal levels of spinophilin, which was
specifically counteracted by the co-treatment of both drugs (Figure 2E and Figure S1). Thus,
the drugs-induced changes in spinophilin protein levels corroborated the modulation of
spine density described above.
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classified spines (thin, stubby and mushroom) based on shape. (E) Histogram shows the semi-quantitative analysis of
density and (C) spine density as a function of dendritic branch order. (D) Spine density of the
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3.3.
Changes in Striatal MSN Cell Bodies after Continuous Administration of Morphine and/or
method. Scale bar is 5 µm. Abbreviations: m, mushroom; s, stuby; t, thin.
PD168,077
3.3. Given
Changes
in specific
Striatal MSN
Cell Bodies
Continuous
Administration
of Morphine
the
remodeling
of after
the MSNs
dendritic
arbors and
dendritic spines in
and/or PD168,077
response to continuous treatment with morphine or/and PD168,077, we next examined
Given the specific remodeling of the MSNs dendritic arbors and dendritic spines
whether these changes appear together with morphological alterations in the soma (Figin response to continuous treatment with morphine or/and PD168,077, we next examure 3A). We observed that morphine or PD168,077 did not affect the morphology of the
ined whether these changes appear together with morphological alterations in the soma
striatal
MSNs somata, demonstrated by an absence of changes in the size (surface area
(Figure 3A). We observed that morphine or PD168,077 did not affect the morphology of the
and
volume;
and shape
(circularity;
However,
thearea
combined
striatal MSNsFigure
somata,3B,C)
demonstrated
by an
absence of Figure
changes3D).
in the
size (surface
and
treatment
with
both
drugs
significantly
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the
size
of
the
striatal
projecting
neuvolume; Figure 3B,C) and shape (circularity; Figure 3D). However, the combined treatment
rons
(surface
area:
by
33%;
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by
55%)
(Figure
3B,C).
with both drugs significantly increased the size of the striatal projecting neurons (surface
area: by 33%; volume: by 55%) (Figure 3B,C).
3.4. D4 R Activation during Continuous Treatment with Morphine Changes the Passive Properties
and Excitability of Striatal MSNs
Since the continuous treatment with morphine and/or PD168,077 regulated dendritic arborization, dendritic spines density and soma size of striatal MSNs, we hypothesized that their electrical activity might be also altered. We used whole-cell patch-clamp
recordings to evaluate the intrinsic properties and excitability of striatal MSNs from
rats treated for 14 days with vehicle, morphine, PD168,077 or morphine + PD168,077
(Figure 4A). The combined treatment with morphine + PD168,077 yielded significant
differences in several passive and active MSNs membrane properties: (i) increased mem-
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brane capacitance (Figure 4B); (ii) reduced membrane resistance (Figure 4C); (iii) increased
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GIRK1 immunoreactivity (IR) was found in the striatal MSNs displaying a punctate
labeling in the cytoplasm (Figure 5A) and in most of the striatal interneurons (PV, SS, and
ChAT) showing an intense reticulum-like distribution in the soma and primary dendrites
(Figure 5A,B). GIRK2 IR was no detected in the CPu (Figure 5C). Both GIRK1 IR (Figure 5D)
and GIRK2 IR (Figure 5E) were present in almost all dopaminergic cells of the SNc identified
with an anti-TH antibody. GIRK1 IR showed a reticulum-like distribution in the cell bodies
(Figure 5D) whereas GIRK2 was demonstrated in both the perikarya and dendritic branches,
even in those that extend down into the substantia nigra pars reticulata (SNr) (Figure 5E).
The continuous treatment (7 days) with morphine or PD168,077 did not alter GIRK1
IR in the striatal MSNs. However, the combined administration of both drugs produced a significant increase in GIRK1 IR (by 23%) (Figure 5F). No changes in GIRK1
IR were detected in ChAT interneurons (Figure S2A), which were identified by their
morphological characteristics.
In the SNc, GIRK1 IR and GIRK2 IR were significantly downregulated by morphine
(GIRK1: by 10%: GIRK2: by 32%) and PD168,077 (GIRK1: by 15%; GIRK2: by 38%)
(Figure 5G,H). However, the co-administration of morphine with PD168,077 completely
(for GIRK1; Figure 5G) or partially (for GIRK2; Figure 5H) prevented these effects.
We also observed that the expression of GIRK1 and/or GIRK2 was regulated even
after a single dose of morphine and/or PD168,007 in the CPu and SNc, although with a
different pattern (Figure S2B).
3.6. D4 R Activation Counteracts Morphine-Induced Upregulation of MOR IR in the
Striosome-Dendron Bouquets
A subset of striatal MSNs originates a direct striatonigral pathway that has been
highlighted as crucial modulator of dopamine neuron function in the SNc [37–39]. These
direct stritatonigral projections target dopaminergic neurons and its ventrally extending
dendrites, where they form a specialized integrative unit that has been termed ‘striosomedendron bouquet’ [40]. High expression of MOR in the striosome-dendron bouquets [40]
(and own observation) lead to the speculation that morphine and/or PD168,077 treatments
could regulate the levels of this receptor as they do in the CPu [26]. The continuous
treatment with morphine (7 days) induced a rise of MOR immunoreactivity (IR) (by 92%)
that was completely prevented when morphine was administrated together with PD168,077
(Figure 6A,B).
To obtain more information concerning both synaptic plasticity and transmission in
the SN, we used western blot to measure the expression levels of synaptophysin, which
is a presynaptic vesicle protein involved in the final steps of exocytosis and synapse
formation [41]. Consistent with the previous results described above, it was observed that
morphine upregulated synaptophysin (by 30%) in the substantia nigra. The administration
of PD168,077 with morphine completely neutralized morphine-induced changes in the
expression levels of this protein (Figure 6C).
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(Figure 6A,B).
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To obtain more information concerning both synaptic plasticity and transmission in
the4.SN,
we used western blot to measure the expression levels of synaptophysin, which is
Discussion
a presynaptic
vesicle
involved
in the
final stepswhether
of exocytosis
and synapse
The purpose
of protein
the present
study was
to determine
the activation
of D4 R formation
Consistent
with
the previous
results described
above, it neuroplasticity
was observed that
with [41].
the specific
agonist
PD168,077
could modulate
morphine-induced
in the CPu. Prolonged exposure to morphine triggered structural plasticity in the dorsal
striatal MSNs, which mainly consists of the retraction of the dendritic arbor and the loss of
dendritic spines. It is also demonstrated that morphine upregulates MOR in the striatonigral
inputs that exert a direct inhibition over nigral dopamine neurons—i.e., striosome-dendron
bouquets. On the other hand, the continuous stimulation of D4 R during morphine treatment
also induced structural plasticity in the MSNs, in this case yielding an expansion of the
dendritic arbor but restoring dendritic spine density. It was of special interest that the
combined treatment of morphine with the D4 R agonist PD168,077 altered the passive
electrical properties and decreases the excitability of the striatal MSNs, along with changes
in GIRK channels expression levels and the restoring of MOR expression in the striosomedendron bouquets.
4.1. Morphine-Induced Structural Plasticity in Striatal MSNs
There is strong evidence that morphine elicits structural and functional plasticity
mostly in brain regions associated with reward, learning, or incentive motivation, such
as the NAc, VTA, PFC, or hippocampus [5,15,42]. These neuroplastic changes persist for
long after the discontinuation of morphine treatment. In fact, a recent research has found
that morphine-induced alterations in proteins related to synaptic plasticity and cytoskeletal
organization persist even six months after cessation of drug administration [43]. However,
little was known about whether morphine also produced structural plasticity in the CPu,
despite this region is critically involved in drug-related habits formation and consolidation
of addiction [1,8,44].
Results of the present study clearly demonstrated that a continuous treatment with
morphine triggers a retraction of the dendritic arbor and a significant loss of dendritic spines
in the dorsal striatal MSNs. This observation is consistent with previous reports describing
a similar pattern of long-term morphine-induced structural plasticity in several regions
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belonging to the reward circuit [2,5,12,45]. However, more recent studies have highlighted
some contradictory data depicting an opposite effect, especially in the NAc, the orbital
prefrontal cortex and the dentate gyrus of the hippocampus [13–15,46]. These differences
could be attributed to several factors, such as the paradigm of drug administration, the
animal sacrifice time point, the brain region analyzed, or even the cell type studied.
Interestingly, we observed that the retraction of dendrites specifically occurred by a
decrease in the size (length and volume) of the proximal dendrites, while the spines loss
was attributable to a selective downregulation of mushroom and stubby spines on distal
dendrites. The concurrence of these two forms of structural plasticity could have a major
impact on MSNs activity. Firstly, because signals propagation effectiveness throughout
dendrites is highly dependent on their morphology [47–50]. Secondly, because dendritic
spines remodeling is tightly linked to synaptic strength, and therefore to the synaptic
plasticity phenomena [51]. Thus, the selective loss of mushroom spines after prolonged
exposure to morphine could reflects the induction of long-term depression (LTD) processes,
as previously demonstrated in excitatory inputs to the dorsal striatum [52,53]. It should be
noted that these two structural changes took place in specific subregions of the dendritic
arbor, revealing a dichotomy between proximal and distal dendrites. Regarding this,
the existence of a topographic organization of the striatal MSNs inputs has been largely
suggested although not fully unraveled. Proximal dendrites seem to mainly receive intrinsic
shaft connections from striatal interneurons and collateral projections from MSNs, whereas
distal dendrites preferentially support extrinsic projections from the cortex, thalamus, or
midbrain [54,55]. In this perspective, it is likely that morphine, by promoting morphological
changes and therefore affecting synaptic inputs, has a significant impact on the function of
the MSNs of the dorsal striatum and ultimately on their output.
Our results show that, although morphine can induce an overall structural plasticity in
the MSNs of the CPu, it is unable to modify their passive membrane properties and intrinsic
excitability. Interestingly, previous studies have demonstrated that repeated morphine
exposure specifically alters the activity of the NAc MSNs which expressed the dopamine
D2 receptors (D2 R) [56,57]. Thus, as in our analysis we did not identify striatal MSNs
subpopulations—e.g., direct- and indirect-pathway projection neurons—it remains to be
investigated in future works whether morphine specifically mediates changes in one of
them. On special interest will also be to reveal the specific action of morphine on the
striatonigral projection neurons located in the striosomal compartment since this neural
population express MOR and provide direct inputs on nigral dopamine neurons [37–40,58]
and we have observed a morphine-induced increase in MOR expression in the striosomedendron bouquets.
4.2. D4 R Activation Alter Dendritic Arbor Complexity and Spine Density of the Striatal MSNs
Dopamine action on striatal MSNs through its interaction with dopamine receptors has
a major role in both structural and synaptic plasticity occurring in these neurons [59]. In fact,
the existence of opposite processes controlling synaptic plasticity induced by dopamine
in form of LTP or LTD are postulated to be directed by D1 R or D2 R in the direct- and
indirect-pathway MSNs, respectively [60–62]. These data support the classical model for
the independence of the two main striatal pathways outputs [63]. However, this model
is currently under review since recent data are quite conflictive. As an example, a recent
report has described that D1 R is essential for the maintenance of spine plasticity in the
direct-pathway MSNs but it also affects indirect-pathway neurons [64]. This could be
explained on the base of intrinsic connectivity between direct- and indirect-pathways
MSNs or the cross-talk of these neurons via interneurons [62]. In addition, several works
confirm that a certain proportion of MSNs co-express D1 R and D2 R [65,66].
The role of other receptor subtypes different to D1 R and D2 R has been largely undervalued in the context of the CPu despite their expression in both direct- and indirect-pathways
MSNs. Thus, the existence of D4 R and D5 R in the CPu [28,67] opens up the possibility to
discover new dopamine signaling mechanisms underlying striatal plasticity. According
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to our results, we suggest a new role for the D4 R in mediating the regulation of MSNs
morphology by dopamine. Here, we show that prolonged D4 R stimulation by itself expands the MSNs dendritic arbors, as the activation of these receptors increase both the
number of distal dendritic branches and also of their length. This dendritic reshaping
could be related to the ability of D4 R to modulate the expression of the neurotrophic factor
BDNF [36] and the transcription factors CREB and ∆FosB [25], which, in turn, regulates
the transcription of numerous genes encoding for cytoskeleton regulatory proteins [5].
Paradoxically, D4 R stimulation also induces a downregulation of all types of dendritic
spines (i.e., thin, stubby and mushroom), which occurs across the entire dendritic arbor.
However, despite the morphological alterations, the passive membrane properties and
excitability remain unchanged. This effect differs from that previously described for D2 R,
since overexpression of this receptor increases the excitability of the MSNs and decreases
the complexity and length of their dendritic arbors [68].
4.3. D4 R Activation Modulates Morphine-Induced Plasticity
D4 R is at present under the focus of interest because of its possible role in cocaine, amphetamine, nicotine, and alcohol addiction [23,24,69–71]. It also exists strong evidence that
stimulation of the D4 R with the selective agonist PD168,077 disrupts morphine addiction
without affecting its analgesic properties [16]. This effect seems to be the result of an antagonistic receptor–receptor interaction involving a hypothetical D4 R-MOR heterodimer [16,26],
which could exist in several regions were both receptors are co-expressed—striosomal
compartment of the CPu and the SNr [28,72].
The current morphological results demonstrated that D4 R stimulation reversed
morphine-induced alterations in thin and mushroom spines, but not in stubby spines.
The combined D4 R agonist and morphine treatment also leads to an expansion of the
dendritic arbor that is similar to that observed after the exclusive treatment with the
D4 R agonist. In agreement with these results, transcriptome analysis following acute
administration of morphine and PD168,077 provided indications for the modulation of
several genes related with dendritic spine dynamic and synaptic formation—Homer1, Pfn2
and Slitrk1 [73–75] that could be also regulated after their chronic administration. Taken
together, these results suggest that a cross-talk between D4 R and MOR could occur to
modulate specifically structural plasticity of dendritic spines.
A parallel decrease in MSNs excitability was also observed upon morphine and
PD168,077 co-treatments, which was accompanied by related membrane property changes.
According with the increase in membrane capacitance, our results showed an enlargement
of the MSNs cell surface. On the other hand, changes in the intrinsic excitability could be
related with an alteration in the inwardly rectifying K+ currents through a modified function
of GIRK channels [57] upon MOR and/or D4 R activation [76,77]. As a proof of concept, we
checked changes in the protein expression levels of two of the GIRK channels subunits—
GIRK1 and GIRK2—which were previously highlighted by its presumed role in the D4 R
modulation over morphine effects [36]. However, only a significant upregulation of GIRK1
was observed in the CPu after morphine and PD168,077 treatments as no expression change
of GIRK2 was found. It is well established that GIRK1 requires the interaction with other
GIRK subunits to reach the cell surface and therefore to form functional channels [35,78,79].
Thus, further studies will be needed to clearly characterize the subunits that form the GIRK
channel heterotetramers that operates in the dorsal striatal MSNs and its function regarding
the regulation of morphine effects.
In addition to the modulatory effect of D4 R over morphine-induced plasticity in the
CPu, we here also observe two indications of neuroadaptative changes in both the nigral dopamine cells and the striatal projections which regulate its function. Firstly, the
co-administration of morphine and the D4 R agonist PD168,077 restores the expression
levels of MOR in the GABAergic terminals coming up from the striosomal MSNs which
form a network surrounding dopamine nerve cells and its ventrally extending dendrites—
‘striosome-dendron bouquet’ [40]. Regarding this, our own previous observation also

Cells 2022, 11, 31

16 of 19

demonstrated a D4 R modulation of MOR in the striosomal compartment [26]. Secondly,
D4 R activation counteracts morphine-induced downregulation of GIRK1 and GIRK2 subunits in nigral dopamine cells, which could be associated, as occurs in the hypothalamus,
to a reduction in the GIRK channel function [77]. Our hypothesis, which clearly requires
further evaluations, is that D4 R prevents morphine-induced MOR sensitization in the
striatal MSNs, leading to a restoring of GABA signaling [27] from the striatum to the SNc
which ultimately could reestablish nigral dopamine cell excitability and a normal dopamine
output toward the CPu [16,42].
In conclusion, in combination with our previous works that evidence that the stimulation of the D4 R prevents morphine-induced reward but not analgesia, we have demonstrated that D4 R appears as a key regulator of morphine-induced plasticity in the CPu.
Therefore, it is plausible that D4 R may disrupts long-term effects of morphine that drive
ventral-to-dorsal striatal shifts in addiction consolidation. Thus, pharmacological strategies
involving D4 R activation might take advantages as a potential therapeutic strategy for the
safety prescription of morphine for pain relief.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3
390/cells11010031/s1, Figure S1: Changes in spinophilin IR in the CPu after continuous administration
(14 days) of morphine and/or PD168,077. Figure S2: Changes in GIRK1 IR in the striatal ChAT
interneurons and changes in GIRK1 and GIRK2 IR in the CPu and SNc after acute administration of
morphine and/or PD168,077. Table S1: Secondary antibodies used for immunohistochemistry and
western blot.
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